Syngene International’s Board of Directors has approved the unaudited financial results for the quarter and half-year ended September 30, 2025. Standalone revenue reached ₹8,301 million for the quarter, with a profit of ₹662 million. Consolidated revenue for the quarter stood at ₹9,106 million, and profit at ₹671 million. The results, compliant with Ind-AS, are available on the company website.
Financial Performance Overview
Syngene International announced its unaudited standalone and consolidated financial results for Q2 2026, with the Board of Directors approving the results on November 5, 2025.
Key Standalone Figures
For the quarter ended September 30, 2025:
- Revenue from operations: ₹8,301 million
- Total Income: ₹8,443 million
- Profit for the period: ₹662 million
Key Consolidated Figures
For the quarter ended September 30, 2025:
- Revenue from operations: ₹9,106 million
- Total Income: ₹9,260 million
- Profit for the period: ₹671 million
Expense Highlights
The standalone expenses for the quarter include:
- Cost of chemicals, reagents, and consumables consumed: ₹2,012 million
- Employee benefits expense: ₹2,259 million
- Depreciation and amortisation expense: ₹1,001 million
The consolidated expenses for the quarter include:
- Cost of chemicals, reagents and consumables consumed: ₹2,275 million
- Employee benefits expense: ₹2,750 million
- Depreciation and amortisation expense: ₹1,165 million
Additional Information
The results have been prepared in accordance with Indian Accounting Standards (Ind-AS). The company also received a final insurance claim of ₹320 million during Q1 2025 (Apr-Jun) related to a fire incident from December 12, 2016.
Equity and Dividends
The Board of Directors recommended a final dividend of ₹1.25 per equity share which was approved by the shareholders on July 23, 2025.
Source: BSE